Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden on Tuesday, increasing access to the widely popular medications to millions of adults with obesity in the U.S., though the plan would likely face opposition under President-elect Donald Trump's second administration.

Only two in five people taking GLP-1 medication were confident they would maintain their weight loss after stopping the regimen, the survey found.

The Biden administration on Tuesday proposed requiring Medicare and Medicaid to cover weight loss drugs like Wegovy and Ozempic. Why it matters: The rule would expand access to the medications for millions of Americans struggling with obesity,

The Biden-Harris administration proposed a new rule on Tuesday that would expand coverage of the anti-obesity medications known as GLP-1 treatments for Medicare and Medicaid beneficiaries. Medicare is currently only allowed to cover these medications for weight loss if they are prescribed to treat a second condition as well.

It would give millions of people access to weekly injectables that have helped people shed pounds so quickly that some people have labeled them miracle drugs.

Fox News contributor Dr. Marc Siegel explains how the rise in weight loss drugs like Ozempic could 'put a dent' in the 'junk food' industry and potentially combat alcohol abuse.

America's kitchen trash bins are receiving more unwanted food as appetites falter among people taking GLP-1 weight-loss meds, a new study shows.

Poison control centers around the country are warning about a rise in calls of patients overdosing on Ozempic.